第二原发性恶性肿瘤与骨髓瘤治疗：时尚还是事实？
Second primary malignancies and myeloma therapy: fad or fact?
作者信息
Usmani Saad Z
出版信息
Oncotarget. 2012 Sep;3(9):915-6. doi: 10.18632/oncotarget.661.
Abstract
The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.
摘要
低风险患者的风险适应性治疗方法可能包括限制移植后免疫调节药物（IMiD）在发生继发性恶性肿瘤（SPM）可能性较高的患者中的暴露。很可能在2012年我们看到的只是冰山一角，随着进一步随访，SPM可能会成为一种重要的长期后遗症。
相似文献
1
Second primary malignancies and myeloma therapy: fad or fact?第二原发性恶性肿瘤与骨髓瘤治疗：时尚还是事实？
Oncotarget. 2012 Sep;3(9):915-6. doi: 10.18632/oncotarget.661.
2
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.接受或未接受来那度胺治疗的多发性骨髓瘤患者后续发生的原发性恶性肿瘤。
Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.
3
Second primary malignancies in multiple myeloma: an overview and IMWG consensus.多发性骨髓瘤中的第二原发性恶性肿瘤：概述和 IMWG 共识。
Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606.
4
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.老年男性患浆细胞骨髓瘤伴长期沙利度胺和来那度胺暴露后的 B 细胞急性淋巴细胞白血病：病例报告及文献复习。
BMC Cancer. 2019 Nov 27;19(1):1147. doi: 10.1186/s12885-019-6286-9.
5
The risk of secondary primary malignancies after therapy for multiple myeloma.多发性骨髓瘤治疗后发生第二原发性恶性肿瘤的风险。
Leuk Lymphoma. 2015;56(11):3012-21. doi: 10.3109/10428194.2014.974043.
6
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.多发性骨髓瘤自体移植后巩固治疗的两项连续研究结果：沙利度胺、地塞米松和克拉霉素或来那度胺、地塞米松和克拉霉素。
Acta Haematol. 2017;137(3):123-131. doi: 10.1159/000455937. Epub 2017 Mar 30.
7
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.来那度胺治疗背景下的第二原发性恶性肿瘤：对纳入骨髓瘤XI试验的2732例骨髓瘤患者的分析。
Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.
8
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.降低毒性、清髓性异基因移植后用来那度胺维持治疗作为难治/复发骨髓瘤患者的挽救治疗。
Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.
9
Update on second primary malignancies in multiple myeloma: a focused review.多发性骨髓瘤中第二原发恶性肿瘤的研究进展：重点综述。
Leukemia. 2014 Jul;28(7):1423-6. doi: 10.1038/leu.2014.22. Epub 2014 Jan 14.
10
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.BiRd（克拉霉素、来那度胺、地塞米松）：在既往未经治疗的多发性骨髓瘤患者中，长期来那度胺治疗的最新进展。
Blood. 2013 Mar 14;121(11):1982-5. doi: 10.1182/blood-2012-08-448563. Epub 2013 Jan 8.
引用本文的文献
1
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.总治疗 2 和 3 后多发性骨髓瘤患者发生骨髓增生异常综合征和急性白血病的危险因素。
Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19.
本文引用的文献
1
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.新诊断多发性骨髓瘤的总治疗 2 和 3 中的第二恶性肿瘤：维持治疗期间沙利度胺和来那度胺的影响。
Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.
2
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
3
Lenalidomide after stem-cell transplantation for multiple myeloma.来那度胺用于多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
4
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
5
Therapy-related myeloid malignancies in myeloma.骨髓瘤相关髓系恶性肿瘤。
Mediterr J Hematol Infect Dis. 2011;3(1):e2011047. doi: 10.4084/MJHID.2011.047. Epub 2011 Oct 24.
6
Treatment of multiple myeloma.多发性骨髓瘤的治疗。
Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91. doi: 10.1038/nrclinonc.2011.63.
7
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.在后续的 2006-66 试验中，使用 VRD 维持治疗，在基因表达谱定义的低危多发性骨髓瘤中，证实了 Total Therapy 3（2003-33）的优异疗效。
Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.
8
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.基于美法仑的自体移植治疗多发性骨髓瘤后细胞遗传学定义的骨髓增生异常综合征与造血干细胞动员不佳有关：阿肯色州自1989年以来治疗的3000多名患者的经验。
Blood. 2008 Jan 1;111(1):94-100. doi: 10.1182/blood-2007-06-097444. Epub 2007 Sep 25.
9
Antitumor activity of thalidomide in refractory multiple myeloma.沙利度胺在难治性多发性骨髓瘤中的抗肿瘤活性。
N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102.
Zotero 插件